Phase 3 trial of investigational drug, Hematide/peginesatide to treat anaemia ... - pharmabiz.com PDF Print
pharmabiz.comIn a subgroup analysis of CSE events in the EMERALD studies in maintenance treatment of anaemia in dialysis patients, the frequency of CSE events was ...Affymax(R) Receives $30 Million Milestone Payments for Database Lock of Phase

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.